D Orazio & Associates Inc. Cuts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

D Orazio & Associates Inc. lessened its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,989 shares of the company’s stock after selling 1,034 shares during the period. D Orazio & Associates Inc.’s holdings in Teva Pharmaceutical Industries were worth $220,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stifel Financial Corp grew its holdings in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. grew its stake in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after buying an additional 33,277 shares during the period. Thrivent Financial for Lutherans grew its stake in Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $24,314,000. Finally, CWA Asset Management Group LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $3,340,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.57.

Check Out Our Latest Stock Report on TEVA

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $16.84 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $11.83 and a 52-week high of $22.80. The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The business’s 50 day moving average is $20.05 and its two-hundred day moving average is $18.50.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

See Also

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.